

Drug Policy:

Doptelet™ (avatrombopag)

POLICY NUMBER UM ONC_1334	SUBJECT Doptelet™ (avatrombopag)		DEPT/PROGRAM UM Dept	PAGE 1 OF 3
DATES COMMITTEE REVIEWED 06/13/18, 05/08/19, 07/10/19, 12/11/19, 08/12/20, 08/11/21, 11/15/21	APPROVAL DATE November 15, 2021	EFFECTIVE DATE November 29, 2021	COMMITTEE APPROVAL DATES 06/13/18, 05/08/19, 07/10/19, 12/11/19, 08/12/20, 08/11/21, 11/15/21	
PRIMARY BUSINESS OWNER: UM		COMMITTEE/BOARD APPROVAL Utilization Management Committee		
URAC STANDARDS HUM 1	NCQA STANDARDS UM 2		ADDITIONAL AREAS OF IMPACT	
CMS REQUIREMENTS	STATE/FEDERAL REQUIREMENTS		APPLICABLE LINES OF BUSINESS Commercial, Exchange, Medicaid	

I. PURPOSE

To define and describe the accepted indications for Doptelet (avatrombopag) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century Health (NCH) is responsible for processing all medication requests from network ordering providers. Medications not authorized by NCH may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. PREFERRED MEDICATION GUIDANCE FOR INITIAL REQUEST:

1. When health plan Medicaid coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Medicaid coverage provisions take precedence per the [Preferred Drug Guidelines OR](#)
2. When health plan Exchange coverage provisions-including any applicable PDLs (Preferred Drug Lists)-conflict with the coverage provisions in this drug policy, health plan Exchange coverage provisions take precedence per the [Preferred Drug Guidelines OR](#)

3. For Health Plans that utilize NCH UM Oncology Clinical Policies as the initial clinical criteria, the [Preferred Drug Guidelines](#) shall follow [NCH L1 Pathways](#) when applicable, otherwise shall follow NCH drug policies **AND**
4. Continuation requests of previously approved, non-preferred medication are not subject to this provision **AND**
5. When applicable, generic alternatives are preferred over brand-name drugs.

B. Thrombocytopenia in Chronic Liver Disease

1. **NOTE:** Per NCH Policy, Doptelet (avatrombopag) is the preferred agent to increase platelet counts in members with thrombocytopenia associated with chronic liver disease. This recommendation is based on the lack of Level 1 evidence (randomized trial and or meta-analysis) showing superior outcomes with Mulpleta (lusutrombopag) over Doptelet (avatrombopag).
2. Doptelet (avatrombopag) may be used as a single agent if the following criteria are satisfied:
 - a. The member has chronic liver disease **AND**
 - b. A mean baseline platelet count of less than 50,000/mm³ **AND**
 - c. The member is scheduled to undergo an invasive procedure.

C. Idiopathic Thrombocytopenia Purpura (ITP)

1. The member has a diagnosis of relapsed/refractory chronic ITP **AND**
2. The member has had an insufficient response (defined by failure of platelet count to increase and stay above 30,000/mm³) to/has and intolerance or contraindication to corticosteroids, immunoglobulins (IVIG), **AND** Rituxan (rituximab) **AND**
3. Platelet count \leq 30,000/mm³ prior to start of therapy.

III. EXCLUSION CRITERIA

- A. Use after failure with Mulpleta (lusutrombopag) for thrombocytopenia in chronic liver disease.
- B. Dosing exceeds single dose limit of Doptelet (avatrombopag) 60 mg (for chronic liver disease) or 40 mg (for chronic ITP).
- C. Treatment with Doptelet (avatrombopag) exceeds the maximum limit of 15 (20 mg) tablets per month (for chronic liver disease) or 60 (20 mg) tablets per month (for chronic ITP).
- D. Dosing exceeds the treatment duration limit of 5 days (for chronic liver disease).
- E. Investigational use of Doptelet (avatrombopag) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
 1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
 2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
 3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definition of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of $<$ 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.

4. Whether the experimental design, in light of the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

IV. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

V. APPROVAL AUTHORITY

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

VI. ATTACHMENTS

- A. None

VII. REFERENCES

- A. Doptelet prescribing information. AkaRx, Inc., Durham, North Carolina 2021.
- B. Clinical Pharmacology Elsevier Gold Standard 2021.
- C. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, CO 2021.
- D. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2021.
- E. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2021.
- F. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014 Apr 20;32(12):1277-80.
- G. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.